These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

38 related items for PubMed ID: 1829837

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. In vitro differentiation of human neuroblastoma cells caused by vasoactive intestinal peptide.
    Pence JC, Shorter NA.
    Cancer Res; 1990 Aug 15; 50(16):5177-83. PubMed ID: 2379178
    [Abstract] [Full Text] [Related]

  • 3. Effects of secretin and gastric inhibitory polypeptide on human pancreatic growth hormone-releasing factor(1-40)-stimulated growth hormone levels in the rat.
    Murphy WA, Lance VA, Sueiras-Diaz J, Coy DH.
    Biochem Biophys Res Commun; 1983 Apr 29; 112(2):469-74. PubMed ID: 6405744
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
    Sotomayor S, Carmena MJ, Schally AV, Varga JL, Sánchez-Chapado M, Prieto JC, Bajo AM.
    Int J Oncol; 2007 Nov 29; 31(5):1223-30. PubMed ID: 17912451
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Effects of endocrine peptides on proliferation, migration and differentiation of human endothelial cells].
    Marion-Audibert AM, Nejjari M, Pourreyron C, Anderson W, Gouysse G, Jacquier MF, Dumortier J, Scoazec JY.
    Gastroenterol Clin Biol; 2000 Nov 29; 24(6-7):644-8. PubMed ID: 10962388
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Synergistic effects of muscarinic agonists and secretin or vasoactive intestinal peptide on the regulation of tyrosine hydroxylase activity in sympathetic neurons.
    Ip NY, Zigmond RE.
    J Neurobiol; 2000 Jan 29; 42(1):14-21. PubMed ID: 10623897
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Properties of vasoactive intestinal peptide-receptor interaction in rat liver membranes.
    Guerrero JM, Prieto JC, Ramírez-Cárdenas R, Calvo JR, Goberna R.
    Rev Esp Fisiol; 1981 Mar 29; 37(1):1-8. PubMed ID: 6113623
    [Abstract] [Full Text] [Related]

  • 18. Interaction of vasoactive intestinal peptide (VIP) with a mouse adrenal cell line (Y-1): specific binding and biological effects.
    Morera AM, Cathiard AM, Laburthe M, Saez JM.
    Biochem Biophys Res Commun; 1979 Sep 12; 90(1):78-85. PubMed ID: 227394
    [No Abstract] [Full Text] [Related]

  • 19. Vasoactive intestinal peptide: a growth promoter in neuroblastoma cells.
    Wollman Y, Lilling G, Goldstein MN, Fridkin M, Gozes I.
    Brain Res; 1993 Oct 08; 624(1-2):339-41. PubMed ID: 8252411
    [Abstract] [Full Text] [Related]

  • 20. VIP potentiates retinoic-acid effect on tissue transglutaminase activity in human neuroblastoma, the SK-N-SH cells.
    Goossens JF, Manechez D, Pommery N, Formstecher P, Hénichart JP.
    Neuropeptides; 1993 Feb 08; 24(2):99-103. PubMed ID: 8096334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 2.